127 related articles for article (PubMed ID: 2357863)
1. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.
Zhou HH; Anthony LB; Roden DM; Wood AJ
Clin Pharmacol Ther; 1990 Jun; 47(6):686-93. PubMed ID: 2357863
[TBL] [Abstract][Full Text] [Related]
2. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
Marathe PH; Shen DD; Nelson WL
Drug Metab Dispos; 1994; 22(2):237-47. PubMed ID: 8013280
[TBL] [Abstract][Full Text] [Related]
3. Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man.
Yasuhara M; Yatsuzuka A; Yamada K; Okumura K; Hori R; Sakurai T; Kawai C
J Pharmacobiodyn; 1990 Nov; 13(11):681-7. PubMed ID: 2093126
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
Edeki TI; He H; Wood AJ
JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
[TBL] [Abstract][Full Text] [Related]
5. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
[TBL] [Abstract][Full Text] [Related]
6. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of pharmacokinetic interaction between propranolol and quinidine in rats.
Yamada K; Yasuhara M; Yatsuzuka A; Okumura K; Sakurai T; Kawai C; Hori R
Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1876-9. PubMed ID: 1394707
[TBL] [Abstract][Full Text] [Related]
8. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
[TBL] [Abstract][Full Text] [Related]
9. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
10. The effect of quinidine, propranolol and their combination on experimental atrial and ventricular arrhythmias.
Lawson JH; Wojciechowski NJ
Arch Int Pharmacodyn Ther; 1977 Oct; 229(2):235-43. PubMed ID: 596978
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
Laganière S; Davies RF; Carignan G; Foris K; Goernert L; Carrier K; Pereira C; McGilveray I
Clin Pharmacol Ther; 1996 Sep; 60(3):255-64. PubMed ID: 8841148
[TBL] [Abstract][Full Text] [Related]
12. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
Broly F; Vandamme N; Caron J; Libersa C; Lhermitte M
Life Sci; 1991; 48(26):PL123-8. PubMed ID: 2046473
[TBL] [Abstract][Full Text] [Related]
13. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
Shaheen O; Biollaz J; Koshakji RP; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1989 Apr; 45(4):439-43. PubMed ID: 2702801
[TBL] [Abstract][Full Text] [Related]
14. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
[TBL] [Abstract][Full Text] [Related]
15. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1999 Jul; 290(1):413-22. PubMed ID: 10381807
[TBL] [Abstract][Full Text] [Related]
16. Multiple pathways of propranolol's metabolism are inhibited by debrisoquin.
Anthony L; Koshakji R; Wood AJ
Clin Pharmacol Ther; 1989 Sep; 46(3):297-300. PubMed ID: 2776392
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.
Murdoch DL; Thomson GD; Thompson GG; Murray GD; Brodie MJ; McInnes GT
Br J Clin Pharmacol; 1991 Mar; 31(3):323-32. PubMed ID: 2054272
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
